VP4 Stock Overview
Through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Vistin Pharma ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 1.99 |
| 52 Week High | NOK 2.29 |
| 52 Week Low | NOK 1.90 |
| Beta | 0.79 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 105.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| VP4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -6.6% | 0.8% |
| 1Y | n/a | -27.7% | 14.6% |
Return vs Industry: Insufficient data to determine how VP4 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how VP4 performed against the German Market.
Price Volatility
| VP4 volatility | |
|---|---|
| VP4 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: VP4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine VP4's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 73 | Magnus Tolleshaug | www.vistin.com |
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is based in Oslo, Norway.
Vistin Pharma ASA Fundamentals Summary
| VP4 fundamental statistics | |
|---|---|
| Market cap | €94.85m |
| Earnings (TTM) | €6.62m |
| Revenue (TTM) | €38.00m |
14.3x
P/E Ratio2.5x
P/S RatioIs VP4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VP4 income statement (TTM) | |
|---|---|
| Revenue | NOK 440.66m |
| Cost of Revenue | NOK 146.62m |
| Gross Profit | NOK 294.04m |
| Other Expenses | NOK 217.25m |
| Earnings | NOK 76.79m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 15, 2025
| Earnings per share (EPS) | 1.73 |
| Gross Margin | 66.73% |
| Net Profit Margin | 17.43% |
| Debt/Equity Ratio | 0% |
How did VP4 perform over the long term?
See historical performance and comparisonDividends
5.0%
Current Dividend Yield72%
Payout RatioDoes VP4 pay a reliable dividends?
See VP4 dividend history and benchmarks| Vistin Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Jun 04 2025 |
| Dividend Pay Date | Jun 12 2025 |
| Days until Ex dividend | 17 days |
| Days until Dividend pay date | 25 days |
Does VP4 pay a reliable dividends?
See VP4 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 10:16 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vistin Pharma ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |